Grifols (GIFLF) Long-Term Deferred Tax (2009 - 2025)
Grifols' (GIFLF) quarterly Long-Term Deferred Tax came in at $484.2 million in Q4 2025, up 32.5% on a YoY basis from $365.5 million in Q4 2024, and up 32.5% quarter-over-quarter from $365.5 million in Q4 2024.
Analysis
Grifols (GIFLF) Long-Term Deferred Tax (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Long-Term Deferred Tax for 17 consecutive years, with $484.2 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Long-Term Deferred Tax rose 32.5% year-over-year to $484.2 million; the trailing twelve-month figure through Dec 2025 stood at $484.2 million (up 32.5% YoY), and the FY2025 full-year result was $470.0 million, up 28.61% from the prior year.
- Long-Term Deferred Tax improved to $484.2 million in Q4 2025 per GIFLF's latest filing, from $365.5 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $323.1 billion in Q4 2023 and bottomed at $174.5 million in Q4 2021.
- Historically, Long-Term Deferred Tax has averaged $100.5 billion across 5 years, with a median of $484.2 million in 2025.
- The sharpest annual moves came in 2022 and 2024: Long-Term Deferred Tax jumped 102193.4% in 2022, then tumbled 99.89% in 2024.
- Over 5 years, Long-Term Deferred Tax stood at $174.5 million in 2021, then surged by 102193.4% to $178.5 billion in 2022, then soared by 81.06% to $323.1 billion in 2023, then sank by 99.89% to $365.5 million in 2024, then soared by 32.5% to $484.2 million in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $484.2 million, $365.5 million, and $323.1 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 484.24 Mn |
| Dec 31, 2024 | 365.46 Mn |
| Dec 31, 2023 | 323.14 Bn |
| Dec 31, 2022 | 178.46 Bn |
| Dec 31, 2021 | 174.46 Mn |
| Dec 31, 2020 | 178.75 Mn |
| Dec 31, 2019 | 136.17 Mn |
| Dec 31, 2018 | 128.45 Mn |
| Jun 30, 2018 | 80.03 Mn |
| Dec 31, 2017 | 77.90 Mn |
| Jun 30, 2017 | 85.92 Mn |
| Dec 31, 2016 | 72.58 Mn |
| Sep 30, 2016 | 76.38 Mn |
| Jun 30, 2016 | 74.38 Mn |
| Dec 31, 2015 | 73.21 Mn |
| Sep 30, 2015 | 74.84 Mn |
| Jun 30, 2015 | 79,576.80 |
| Mar 31, 2015 | 92.69 Mn |
| Dec 31, 2014 | 103.04 Mn |
| Sep 30, 2014 | 149.28 Mn |